Avatrombopag (Doptelet)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 02:46, 2 December 2016 by Dryang (talk | contribs) (Text replacement - "http://www.ncbi.nlm" to "https://www.ncbi.nlm")
Jump to navigation Jump to search

Mechanism of action

Thrombopoietin receptor agonist

Preliminary data

Autoimmune thrombocytopenic purpura (ITP)

Randomized Phase II, >20 per arm

  1. Bussel JB, Kuter DJ, Aledort LM, Kessler CM, Cuker A, Pendergrass KB, Tang S, McIntosh J. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014 Jun 19;123(25):3887-94. Epub 2014 May 6. link to original article PubMed

Also known as

YM477, AKR 501

Retrieved from "https://hemonc.org/w/index.php?title=Avatrombopag_(Doptelet)&oldid=12558"